United States: The Third Circuit Gives the Green Light to RICO Plaintiffs Seeking to Recover Payments for Prescription Drugs

This week, the Third Circuit altered the legal landscape for civil Racketeer Influenced and Corrupt Organizations Act (RICO) claims against pharmaceutical companies. The ruling in In re Avandia Marketing, Sales Practices & Product Liability Litigation allows the plaintiffs' RICO claims to proceed; in their suit, the plaintiffs allege that GlaxoSmithKline LLC (GSK) engaged in a marketing campaign to minimize the side effects of Avandia, a drug prescribed to treat Type II diabetes, and thereby increase sales at a higher price than it otherwise would have been sold.

The plaintiffs alleged claims under § 1964(c) of RICO. According to the plaintiffs, GSK violated RICO by committing predicate acts of wire fraud, mail fraud, tampering with witnesses, and use of interstate facilities to conduct unlawful activity. Plaintiffs allege that GSK engaged in these predicate acts through a marketing campaign designed to boost confidence in Avandia's safety.

The plaintiffs, union welfare funds that pay for prescription coverage for their enrollees, argue that they lost money due to GSK's misrepresentations and brought the suit as a class action. As third-party payors (TPPs), the plaintiffs pay for all or some of the cost of drugs that the TPP has listed on its formulary. The formulary is comprised of drugs that have been evaluated for safety, efficacy, and cost effectiveness.

After a trial court denied GSK's motion to dismiss, the Third Circuit's ruling came as part of an interlocutory appeal on the issues of whether the plaintiffs have standing and whether the complaint adequately alleged proximate causation. The Third Circuit found in favor of the plaintiffs on both questions.

On appeal, GSK contended that the plaintiffs did not have standing because they lacked a concrete injury to business or property within the meaning of RICO. Specifically, GSK relied on the Third Circuit's decision in Maio v. AETNA, Inc. to argue that the plaintiffs' allegations were too dependent on future events, such as Avandia being unsafe or ineffective. In Maio, the Third Circuit concluded that health insurance beneficiaries could not maintain a RICO claim for economic injury against their insurer based on alleged misrepresentations regarding the services included in their HMO plans. Rejecting the plaintiffs' argument that they had paid high premiums for inferior health insurance, the Third Circuit found that the plaintiffs suffered no cognizable injury because their theory of injury was premised solely on the possibility that they might receive inadequate healthcare in the future.

Unpersuaded by GSK's analogy to Maio, the court here held that Maio was distinguishable in one crucial respect—the plaintiffs' injury was not contingent on future events. The Third Circuit held  that this case was more closely analogous to In re Warfarin Sodium Antitrust Litigation, in which TPPs alleged that the defendant violated antitrust law by spreading false information about a competitor drug, causing the TPPs to pay for the defendant's more expensive drug. In Warfarin, the Third Circuit held that TPPs do suffer a direct economic harm when, as a result of the pharmaceutical company's misrepresentation, they pay supracompetitive prices for brand name drugs. The Third Circuit extended the Warfarin court's reasoning to claims brought under RICO, finding that the TPPs adequately alleged that they had suffered direct economic harm as a result of GSK's alleged misrepresentations.

The court was unpersuaded by GSK's contention that no concrete injury existed because TPPs can anticipate fraud and, thus avoid harm by passing on that cost to their enrollees by way of higher premiums. The court noted that, at the motion to dismiss stage, no evidence supported GSK's argument and, further, the argument had no limiting principle. For example, if adopted, such a theory could be used to bar stores from recovering for shoplifting based on the presumption that their pricing model accounted for theft.

GSK also argued that the plaintiffs had not adequately alleged proximate causation because the presence of intermediaries—physicians and patients—in the causal chain rendered any harm too indirect. The court surveyed precedent on RICO causation, beginning with Holmes v. Securities Investor Protection Corp. In Holmes, the U.S. Supreme Court addressed the overbreadth concerns inherent in the language of § 1964(c) by setting out the three factors courts should assess in evaluating causation under RICO: (1) the directness of the injury; (2) the risk of multiple recoveries; and (3) the likelihood of vindication by others.

Considering these factors, the Holmes Court determined that a plaintiff-subrogee had failed to satisfy RICO's proximate cause requirement. In that case, the plaintiff alleged that the defendant manipulated a stock, which led two broker-dealers to insolvency and later required the plaintiff to reimburse the broker-dealers' customers' losses. The Court refused to find an adequate causal connection because "the link [was] too remote between the stock manipulation alleged and the customers' harm, being purely contingent on the harm suffered by the broker-dealers."

In contrast to Holmes, proximate cause will be found if a sufficiently direct relationship exists between a defendant's wrongful conduct and a plaintiff's injury. This is true even if a RICO plaintiff did not directly rely on the defendant's misrepresentation. The Third Circuit determined that proximate causation can be found where the conduct that allegedly caused the plaintiff's injuries is identical to the acts that form the basis of the RICO scheme. Further, the injury alleged by the TPPs is an economic injury independent of any physical injury suffered by Avandia users. Joining the First Circuit, the court found that doctors do not break the chain of causation because it was not the doctors' decision to prescribe Avandia that caused the plaintiffs' injuries.

Without opining on the likelihood of success of the plaintiffs' claims, the court concluded that the TPPs had adequately alleged standing and proximate causation. The court's decision adds clarity to the requirements for successfully pleading under § 1964(c) of RICO, and it may clear the way for similar litigation against pharmaceutical companies.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions